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or patients with moderate to severe psoriasis,
long-term treatment is usually required for
adequate disease control.1-4 Conventional sys-
temic therapies have been used for decades,
but long-term usage is sometimes associated with
organ-specific toxicity.5,6 Current biologic therapies
have improved clinical management of psoriasisment of Dermatology, University of Connecticut
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himotsuke, Tochigie; Innovaderm Research,because of a favorable benefit-risk balance without
cumulative organ-specific toxicity.7-16
Recently published data from randomized trials
involving the anti-interleukin (IL)-17A monoclonal
antibodies, secukinumab,17,18 ixekizumab,19,20 and
brodalumab,21,22 raised expectations for improved
management of psoriasis. However, as with any newMontrealf; Department of Dermatology, University of Pitts-
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We report an integrated safety analysis from 7
psoriasis clinical trials involving ixekizumab.
METHODS
Patients and study design
Main data sources were UNCOVER-1, UNCOVER-
2, and UNCOVER-3, randomized, double-blind,
placebo-controlled phase III trials of ixekizumab in
psoriasis.19,20 Adult patients (age $18 years) withSupported by Eli Lilly and Company.
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PY: patient year
SAE: serious adverse event
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TEAE: treatment-emergent adverse event
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Strober et al 3included in the Primary Psoriasis Placebo-ControlledCAPSULE SUMMARY
d Ixekizumab is an antieinterleukin-17A
antibody.
d During induction, incidence rates per
100 patient-years of most adverse events
of special interest were comparable in
the ixekizumab and etanercept groups.
d No unexpected safety signals were
observed during ixekizumab
maintenance therapy.Integrated Analysis Set
(UNCOVER-1, -2, and -3)
and the Psoriasis Placebo-
and Active-Controlled
Integrated Analysis Set
(UNCOVER-2 and -3). For
the induction period,
Primary Psoriasis Placebo-
Controlled Inte-grated
Analysis Set data were used
to make comparisons be-
tween ixekizumab and pla-
cebo, and Psoriasis Placebo-
and Active-Controlled
Integrated Ana-lysis Set data
were used to make comparisons between ixekizu-
mab and etanercept. The Psoriasis Maintenance
Integrated Analysis Set comprised ixekizumab
responders from the UNCOVER-1 and -2 induction
periods who were re-randomized at week 12
to either maintenance treatment or treatment
withdrawal to week 60. Data in the All Psoriasis
Ixekizumab Exposures Analysis Set, which
integrates all ixekizumab doses and study periods,
were pooled from 7 clinical trials (Supplementary
Table I).19,20,23-26 Data cut-off was April 9, 2015.
Protocols received ethical review board approval;
patients gave written informed consent.Safety evaluations
The safety population consisted of all randomized
patients receiving 1 or more doses of study
treatment. The Maintenance Dosing Period Primary
Population consisted of all re-randomized patients
receiving 1 or more doses of study treatment during
the maintenance period. Adverse events (AEs) were
classified based on the Medical Dictionary for
Regulatory Activities versions 17.0 (Primary
Psoriasis Placebo-Controlled Integrated Analysis Set
and Psoriasis Placebo- and Active-ControlledIntegrated Analysis Set) and 17.1 (Psoriasis
Maintenance Integrated Analysis Set and All
Psoriasis Ixekizumab Exposures Analysis Set).
A treatment-emergent AE (TEAE) was an event first
occurring or worsening in severity after baseline and
on or before the last day within the treatment period.
Lowest level terms were used for the TEAE
computation and preferred terms are presented.
Exposure-adjusted incidence rates (IRs) for TEAEs
represent the number of patients with a particular
event per 100 patient-years (PY) of exposure. Time
during the treatment period was considered entire
exposure time. If an event occurred multiple times
for a patient, the event was counted once.Neutropenia was defined
as Common Terminology
Criteria for AE grade 2 or
greater (absolute neutrophil
count \1.5 3 109/L). Infe-
ction events with onset date
14 days or less before or after
the grade-2 neutrophil count
collection date were consid-
ered infections preceded or
accompaniedbyneutropenia.
Data for inflammatory
bowel disease (IBD) are
presented as reported by
the investigator, not as adju-
dicated. Adjudicated datawill be presented in a future publication.
Statistical methods
Treatment comparisons for frequencies were
analyzed using the Cochran-Mantel-Haenszel test
stratified by study.27 A Poisson regression model
(treatment as explanatory variable) was used
to compare exposure-adjusted IRs.28 In the
induction period, statistical comparisons between
ixekizumab and placebo were conducted within
Primary Psoriasis Placebo-Controlled Integrated
Analysis Set, and statistical comparisons between
ixekizumab and etanercept were conducted within
the Psoriasis Placebo- and Active-Controlled
Integrated Analysis Set. Statistical tests with 2-sided
P values less than .05 were considered statistically
significant.
RESULTS
Patients and exposure
Overall, 4209 patients received 1 or more doses
of ixekizumab with a total exposure of 6480 patient-
years (median 507 days; maximum 1794 days) (Fig 1
and Table I). Supplementary Table II shows patient
demographics.
Table I. Databases and exposure
Treatment period
Integrated analysis
data set Treatment
No. of
patients*
Median
(minimum, maximum)
patient-days of exposure Patient-years
Induction period Primary Psoriasis
Placebo-Controlled
Integrated Analysis Set
(UNCOVER-1, -2, and -3)
Placebo 791 85.0 (8, 183) 180.0
IXE 80 mg Q4W 1161 85.0 (1, 197) 265.9
IXE 80 mg Q2W 1167 85.0 (8, 116) 268.6
Total IXE 80 mg 2328 85.0 (1, 197) 534.5
Psoriasis Placebo- and
Active-Controlled
Integrated Analysis Set
(UNCOVER-2 and -3)
Placebo 360 85.0 (11, 146) 83.2
IXE 80 mg Q4W 729 85.0 (1, 197) 167.6
IXE 80 mg Q2W 734 85.0 (8, 116) 168.9
Total IXE 80 mg 1463 85.0 (1, 197) 336.5
Etanercept 739 85.0 (7, 217) 169.2
Maintenance
period
Psoriasis Maintenance
(PsM; UNCOVER-1 and -2)y
Placebo 402 152.0 (20, 423) 188.2
IXE 80 mg Q12W 408 316.0 (1, 361) 282.4
IXE 80 mg Q4W 416 337.0 (24, 434) 345.2
Total IXE 80 mg 824 336.0 (1, 434) 627.6
All treatment
periods
All Psoriasis IXE Exposures
Analysis Set (UNCOVER-1,
-2, and -3 plus an additional
4 phase I-III studies)
Total pooled IXE 4209 507.0 (1, 1794) 6479.8
UNCOVER-1, NCT01474512; UNCOVER-2, NCT01597245; and UNCOVER-3, NCT01646177.
IXE, Ixekizumab; PsM, Psoriasis Maintenance Integrated Analysis Set; Q2W, every 2 weeks; Q4W, every 4 weeks; Q12W, every 12 weeks.
*The exposure numbers for the induction, maintenance period, and overall categories at any time (ie, all psoriasis) cannot be summed across
categories.
y1226 Patients who were responders to treatment during the induction (as measured by static Physician Global Assessment [0,1] at wk 12)
and were then re-randomized in the maintenance period were included in PsM (UNCOVER-1 and -2).
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Induction period: ixekizumab versus etaner-
cept (Psoriasis Placebo- and Active-Controlled
Integrated Analysis Set; UNCOVER-2 and
-3). The IRs of TEAEswere similar in the ixekizumab
groups and the etanercept group (Supplementary
Table III; Supplementary Appendix for Primary
Psoriasis Placebo-Controlled Integrated Analysis
Set). Most TEAEs were mild or moderate. The overall
safety profile of etanercept was comparable with
ixekizumab. The most common TEAE type was
infection. The IRs of infections were significantly
higher in the total ixekizumab group than in the
etanercept group, but this was not true for individual
infection types. The IRs of injection-site reactions
(ISRs) were similar in ixekizumab- and etanercept-
treated patients. However, among individual types of
ISRs, the IR of injection-site pain was higher in
patients treated with ixekizumab every 2 weeks
compared with etanercept-treated patients, and the
IR of injection-site erythema was lower in patients
treated with ixekizumab every 4 weeks compared
with etanercept-treated patients.
The IRs of serious AEs (SAEs) and discontinua-
tions because of AEs did not significantly differbetween the ixekizumab and the etanercept
groups (Supplementary Table III). The IRs of
individual SAEs and discontinuations because of
AEs were also similar in the ixekizumab and
etanercept groups. No deaths occurred during the
induction period.
Maintenance period (Psoriasis Maintenance
Integrated Analysis Set; ixekizumab only). Du-
ring maintenance, no significant differences were
observed in the IRs of TEAEs between groups taking
ixekizumab every 4 weeks and every 12 weeks
(Supplementary Table IV). Most TEAEs were
mild or moderate (Supplementary Table IV).
Nasopharyngitis was the most common TEAE with
ixekizumab. SAEs occurring in 2 or more patients in
the total ixekizumab group were falls, coronary
artery disease, inguinal hernia, osteoarthritis, and
intervertebral disc protrusion. In the total ixekizu-
mab group, the IRs of discontinuations because of
AEwere low; themost common reasons were related
to protocol-mandated discontinuation of patients
with positive tuberculosis (TB) test results.
However, there were no cases of clinically active
or reactivated TB. Two deaths occurred in the
maintenance period (Supplementary Table V).
Fig 1. Psoriasis. Drug exposure. The number of patients exposed to ixekizumab. In the
Psoriasis Placebo- and Active-Controlled Integrated Analysis Set, the median exposure times
were 85.0 days (maximum 197) for ixekizumab every 4 weeks (Q4W) and 85.0 days (maximum
116) for ixekizumab every 2 weeks (Q2W). The median exposure time for patients in
the Psoriasis Maintenance Integrated Analysis Set treated with ixekizumab Q2W induction
dosing/Q4W maintenance dosing was 337.0 (maximum 370) and with ixekizumab Q4W/Q4W
was 337.0 days (maximum 434).
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Set. Supplementary Table VI shows common
TEAEs, SAEs, and AEs leading to discontinuation in
the All Psoriasis Ixekizumab Exposures Analysis Set.
There were 10 fatalities among all entered patients
with psoriasis (8 ixekizumab [0.1 per 100 PY]; 1
etanercept; 1 nonrandomized) (Supplementary
Table V); the majority of deaths were a result of
cardiovascular events.AEs of special interest
Infections were most often nonserious, mild, or
moderate infections of the upper respiratory tract.
The IRs of serious infections were similar in the
ixekizumab groups and the etanercept group during
the induction period (Fig 2, A, and Supplementary
Table VII); erysipelas (n = 2) was the only serious
infection reported by 1 or more ixekizumab-treated
patient. No serious infection occurred in more than 1
ixekizumab-treated patient in the Psoriasis
Maintenance Integrated Analysis Set. Cellulitis
(n = 17; 0.4%) was the most common serious
infection in the All Psoriasis Ixekizumab Exposures
Analysis Set. The frequencies of infections were not
greater for ixekizumab-treated patients comparedwith placebo-treated patients with preceding or
accompanying neutropenia grade 2 or higher.
In the All Psoriasis Ixekizumab Exposures
Analysis Set, 36 ixekizumab-treated patients had
positive TB test results, and 13 patients were re-
ported to have latent TB during yearly evaluation
(Supplementary Table VI). There were no cases of
clinically active or reactivated TB in ixekizumab
clinical trials.
There were no invasive fungal infections
involving candidemia or deep organ infection iden-
tified in any treatment period, nor were there
discontinuations because of Candida infections. Of
165 (2.5 per 100 PY) reported Candida cases in the
All Psoriasis Ixekizumab Exposures Analysis Set (Fig
2, B, and Supplementary Table VII), 5 (0.1% of all
patients) were assessed by the investigator as severe.
In over 80% of all patients with Candida-related
events, infection(s) had either resolved or were
resolving by database lock per investigator
judgement. The most frequently occurring Candida
infections included vulvovaginal candidiasis (2.4
per 100 PY) and oral candidiasis (1.2 per 100 PY)
(Fig 2, C ).
During the induction period, the IRs of oral
candidiasis were 0 per 100 PY in placebo group,
A B C
F
IHG
D E
Fig 2. Psoriasis. Adverse events (AEs) of special interest. Exposure-adjusted incidence rates
(IRs)/100 patient-years (PY ). The exposure-adjusted IRs for treatment-emergent AEs represent
the number of patients with a particular event/100 PY of exposure. Time during the treatment
period was considered entire exposure time. The symbol is the exposure-adjusted IR and the
bars are 95% confidence intervals. During the induction period, the IRs are from the Psoriasis
Placebo (PBO)- and Active-Controlled Integrated Analysis Set. A, Serious infections. B,
Candida (high-level terms [HLTs] and clinical terms). C, Oral Candida (HLTs and clinical
terms). D, Nonmelanoma skin cancers (NMSC ). E, Malignancies excluding NMSC. F, Crohn’s
disease.G, Ulcerative colitis.H, Major adverse cardiovascular events (MACE ); total PY is 6026.4
for MACE because adjudication was only performed for the phase (Ph) III trials. I, Injection-site
reactions (composite of injection site reactionerelated terms). ETN, Etanercept; IXE, ixekizu-
mab 80 mg; LTE, long-term extension; Ps, psoriasis; Q2W, every 2 weeks; Q4W, every 4 weeks;
Q12W, every 12 weeks; RCT, randomized-controlled trial; WD, withdrawal.
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every 4 weeks groups, and 3.6 per 100 PY in the
ixekizumab every 2weeks group (Fig 2,C ). In the All
Psoriasis Ixekizumab Exposures Analysis Set, the
median duration of oral Candida infections was
5 weeks; of 78 patients, 3 had a severe event. Among
all patients, 8 cases (0.1 per 100 PY) of esophageal
candidiasis were reported in patients either receiving
or recently administered ixekizumab; of these, 2
were SAEs and 4 were confirmed with esophagogas-
troduodenoscopy. Most patients with esophageal
candidiasis received oral fluconazole alone or with
other agents. In all cases, the events resolved, and
the patients remained on study.The IRs of nonmelanoma skin cancers (NMSC)
and malignancies excluding NMSC were low (Fig 2,
D and E, and Supplementary Table VII). Of malig-
nancies excluding NMSC, there was no pattern of
tumor type (Supplementary Table VIII). In all, 22
patients had malignancies leading to discontinua-
tion; no patient with NMSC discontinued.
Overall, the incidences of reported Crohn’s dis-
ease (Fig 2, F ) and ulcerative colitis (Fig 2, G) were
low. During the induction period, 1 case (0.3 per
100 PY) of newly diagnosed Crohn’s disease and 1
case (0.3 per 100 PY) of an exacerbation of ulcer-
ative colitis was reported in ixekizumab-treated
patients, whereas no etanercept-treated patient
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Ixekizumab Exposures Analysis Set, 3 and 5
ixekizumab-treated patients discontinued because
of Crohn’s disease and ulcerative colitis, respec-
tively. There were 4 patients with pre-existing
Crohn’s disease, none of whom reported an
exacerbation during the trials, and 10 patients
with pre-existing ulcerative colitis at enrollment, 4
of whom had flares during study participation.
During the induction period, the between-group
rates of adjudicated major adverse cardiovascular
events (MACE) were similar (Fig 2, H ). The MACE
individual components did not change substantially
with longer exposure to ixekizumab. In the All
Psoriasis Ixekizumab Exposures Analysis Set,
the IR of adjudicated MACE was 0.6 per 100 PY
(median time to onset 254.0 days). Of 4035
ixekizumab-treated patients participating in trials
with independent MACE adjudication, 7 patients
experienced vascular death (Supplementary Tables
V and VIII). With the exception of 1 nonfatal stroke,
all MACE were SAEs. At baseline, patients subse-
quently developing treatment-emergent MACE had a
higher prevalence of established risk factors for
acute atherothrombotic events than patients without
MACE. After adjustment for exposure, ixekizumab
treatment during the maintenance period was not
associated with clinically meaningful changes in
blood pressure, body weight, blood glucose, or
proatherogenic lipid profile compared with placebo.
There were no completed suicides in the All
Psoriasis Ixekizumab Exposures Analysis Set. The
rate of suicidal ideation or behavior observed was
1.39 per 1000 patient-years; Supplementary Table
VIII lists depression- and self-injury-related TEAEs
occurring in 1 or more patients. The IRs of these
events were similar between ixekizumab treatment
groups. In the All Psoriasis Ixekizumab Exposures
Analysis Set, there were 8 reported suicide attempts;
2 additional events were considered by the sponsor
to be suicide attempts, 1 of which occurred during
patient follow-up 2 months after the last dose of
ixekizumab. Only patients with 1 or more risk factors
attempted suicide; 2 patients had undisclosed history
of suicide attempts, a study exclusion criterion.
Depression- and self-injury-related events also
occurred in patients treated with placebo (1 suicide
attempt in the phase I study, which is not included in
the integrated data sets) and etanercept (1 suicidal
ideation).
During the induction period, the IRs of ISRs
were similar in the total ixekizumab and etanercept
groups (Fig 2, I ). Most ISRs in ixekizumab-treated
patients were mild or moderate in severity,
and 53.1% of patients experiencing ISRs had only1 occurrence during induction. In the All
Psoriasis Ixekizumab Exposures Analysis Set, the
median time to occurrence from the first dose to
first occurrence of ISR was 14 days. The median
duration of ISRs was 2.03 days. Eight ixekizumab-
treated patients discontinued because of ISRs.
There were no confirmed cases of ixekizumab-
related anaphylaxis events.
DISCUSSION
With 6480 patient-years of exposure in 4209
patients, we evaluated long-term continuous
follow-up in one of the largest cohorts of patients
with psoriasis treated with an antieIL-17A mono-
clonal antibody in a clinical trial setting. Most
observed AEs were nonserious and did not lead to
treatment discontinuation.
The safety profile reported here is consistent with
previous reports for ixekizumab.19,20 In analyses
presented here, IRs are based on numbers of patients
with events per 100 patient-years of exposure, with
entire time on treatment considered the exposure
time. Ixekizumab-treated patients, compared with
etanercept- and placebo-treated patients, did not
show evidence of an increased risk of suicidal
thoughts and behaviors.
In the 2 trials including etanercept (UNCOVER-2
and -3), the 12-week safety profile for ixekizumab
was comparable with that of etanercept with some
exceptions. A limitation of our data is that direct
comparison between ixekizumab and etanercept
can be made only for the 12-week induction period.
A difference was an increased incidence of oral
candidiasis infections with ixekizumab. This is
consistent with a proposed role of IL-17 in host
defense against extracellular pathogens, including
fungi such as the yeast Candida albicans.29-32 The
use of ixekizumab was not associated with an overall
increased frequency of serious infections (including
TB and invasive fungal infections) during induction.
Cellulitis was the most frequently reported SAE in the
All Psoriasis Ixekizumab Exposures Analysis Set
(0.4%). Cellulitis is typically caused by infection
with Streptococcus pyogenes or Staphylococcus
aureus.33 Patients with deficiency with T helper 17
(Th17) cells (hyper-IgE syndrome [HIES]), IL-17RA,
or IL-17F have increased risk of cutaneous infection
because of Staphylococcus aureus.29,30 It is not
unexpected that cellulitis is themost frequent serious
infection observed in ixekizumab-treated patients.
Patients whose tuberculin skin test or
QuantiFERON (Cellestis, a QIAGEN company,
Melbourne, Australia) test results converted to
positive during the yearly evaluation were
observed. Available evidence suggests that in tested
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Mycobacterium tuberculosis infection, such as the
majority of patients enrolled in these trials, a high
proportion of false-positive findings will be
observed.34-36 Importantly, there were no cases of
clinically active or reactivated TB in the entire
ixekizumab clinical development program.
The rate of malignancies excluding NMSC among
ixekizumab-treated patients was comparable with
etanercept-treated patients during the induction
period. Moreover, the rates of NMSCs and
malignancies excluding NMSC in ixekizumab-
treated patients were consistent with rates expected
in patients with psoriasis.12,37-40 Conclusions on
malignancy risks are, however, limited by the
relatively short-term duration of these trials. In
addition, ixekizumab use was not associated with
an increased risk of MACE.
New onset and exacerbations of Crohn’s disease
and ulcerative colitis occurred in ixekizumab-treated
patients. In the epidemiologic literature, there is
an increased prevalence of IBD among patients
with psoriasis compared with matched control
populations41,42; other studies have shown an
increased risk of IBD in patients with psoriasis or
an increased risk of psoriasis in patients with
IBD.43,44 Because IL-17 inhibitors appear to be
ineffective in the treatment of IBD and may worsen
the condition,45,46 additional evaluation is needed to
understand the association between IBD and IL-17
inhibitors, including ixekizumab. Practitioners
should use caution when considering the use of
ixekizumab in patients with pre-existing IBD.
The rate of suicidal ideation or behavior observed
among patients with psoriasis who were exposed to
ixekizumab was 1.39 per 1000 patient-years, which
is within the range reported for patients with
psoriasis.47
In conclusion, no unexpected safety signals were
observed during maintenance with ixekizumab.
Long-term extension studies are ongoing.REFERENCES
1. Jacobs A, Rosumeck S, Nast A. Systematic review on the
maintenance of response during systemic antipsoriatic
therapy. Br J Dermatol. 2015;173:910-921.
2. Mease PJ, Armstrong AW. Managing patients with psoriatic
disease: the diagnosis and pharmacologic treatment of
psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:
423-441.
3. Mrowietz U. Implementing treatment goals for successful
long-term management of psoriasis. J Eur Acad Dermatol
Venereol. 2012;26 Suppl 2:12-20.
4. Sandoval LF, Pierce A, Feldman SR. Systemic therapies for
psoriasis: an evidence-based update. Am J Clin Dermatol. 2014;
15:165-180.5. Archier E, Devaux S, Castela E, et al. Carcinogenic risks of
psoralen UV-A therapy and narrowband UV-B therapy in
chronic plaque psoriasis: a systematic literature review. J Eur
Acad Dermatol Venereol. 2012;26 Suppl 3:22-31.
6. Pathirana D, Ormerod AD, Saiag P, et al. European
S3-guidelines on the systemic treatment of psoriasis vulga-
ris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1-70.
7. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal anti-
body, in patients with psoriasis: 76-week results from a
randomized, double-blind, placebo-controlled trial (PHOENIX
1). Lancet. 2008;371:1665-1674.
8. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as
monotherapy in patients with psoriasis. N Engl J Med. 2003;
349:2014-2022.
9. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for
moderate to severe psoriasis: a randomized, controlled phase
III trial. J Am Acad Dermatol. 2008;58:106-115.
10. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of
ustekinumab, a human interleukin-12/23 monoclonal anti-
body, in patients with psoriasis: 52-week results from a
randomized, double-blind, placebo-controlled trial (PHOENIX
2). Lancet. 2008;371:1675-1684.
11. Reich K, Nestle FO, Papp K, et al. Infliximab induction and
maintenance therapy for moderate-to-severe psoriasis: a
phase III, multicenter, double-blind trial. Lancet. 2005;366:
1367-1374.
12. Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim
analysis: an observational postmarketing safety registry of
etanercept for the treatment of psoriasis. J Am Acad Dermatol.
2013;68:756-764.
13. Menter A, Thaci D, Papp KA, et al. Five-year analysis from the
ESPRIT 10-year postmarketing surveillance registry of adali-
mumab treatment for moderate to severe psoriasis. J Am Acad
Dermatol. 2015;73:410-419.e6.
14. Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for
ustekinumab and other psoriasis treatments from the psoriasis
longitudinal assessment and registry (PSOLAR). J Drugs
Dermatol. 2015;14:706-714.
15. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of
ustekinumab in patients with moderate-to-severe psoriasis:
final results from 5 years of follow-up. Br J Dermatol. 2013;168:
844-854.
16. Shear NH, Hartmann M, Toledo-Bahena M, et al. Long-term
efficacy and safety of infliximab maintenance therapy in
patients with plaque-type psoriasis in real-world practice. Br
J Dermatol. 2014;171:631-641.
17. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in
plaque psoriasiseresults of two phase 3 trials. N Engl J Med.
2014;371:326-338.
18. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to
ustekinumab in clearing skin of subjects with moderate to
severe plaque psoriasis: CLEAR, a randomized controlled trial.
J Am Acad Dermatol. 2015;73:400-409.
19. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of
ixekizumab with etanercept or placebo in moderate-
to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results
from two phase 3 randomized trials. Lancet. 2015;386:
541-551.
20. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of
ixekizumab in moderate-to-severe plaque psoriasis. New
England Journal of Medicine. 2016;375:345-356.
21. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies
comparing brodalumab with ustekinumab in psoriasis.
N Engl J Med. 2015;373:1318-1328.
J AM ACAD DERMATOL
VOLUME jj, NUMBER j
Strober et al 922. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of
brodalumab for psoriasis after 120 weeks of treatment. J Am
Acad Dermatol. 2014;71:1183-1190.e3.
23. Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label
study of the efficacy and safety of ixekizumab, an
anti-interleukin-17A monoclonal antibody, in patients with
chronic plaquepsoriasis. J AmAcadDermatol. 2014;71:1176-1182.
24. Krueger JG, Fretzin S, Suarez-Farinas M, et al. IL-17A is essential
for cell activation and inflammatory gene circuits in subjects
with psoriasis. J Allergy Clin Immunol. 2012;130:145-154.e9.
25. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17
monoclonal antibody ixekizumab in chronic plaque psoriasis.
N Engl J Med. 2012;366:1190-1199.
26. Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of
open-label ixekizumab treatment in Japanese patients with
moderate-to-severe plaque psoriasis, erythrodermic psoriasis
and generalized pustular psoriasis. J Eur Acad Dermatol
Venereol. 2015;29:1148-1155.
27. Mantel N. Chi-square tests with one degree of freedom;
extensions of the Mantel-Haenszel procedure. J Am Stat Assoc.
1963;58:690-700.
28. Long JS. In: Regression models for categorical and limited
dependent variables. Advanced quantitative techniques in the
social sciences. 1st ed. Number 7. Thousand Oaks, CA: Sage
Publications; 1997.
29. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocuta-
neous candidiasis in humans with inborn errors of
interleukin-17 immunity. Science. 2011;332:65-68.
30. Cypowyj S, Picard C, Marodi L, et al. Immunity to infection in
IL-17-deficient mice and humans. Eur J Immunol. 2012;42:
2246-2254.
31. Gaffen SL, Hernandez-Santos N, Peterson AC. IL-17 signaling in
host defense against Candida albicans. Immunol Res. 2011;50:
181-187.
32. Peck A, Mellins ED. Precarious balance: Th17 cells in host
defense. Infect Immun. 2010;78:32-38.
33. Stevens DL, Bryant AE. Impetigo, erysipelas and cellulitis. In:
Ferretti JJ, StevensDL, Fischetti VA, eds. Streptococcus pyogenes:
basic biology to clinical manifestations. Oklahoma City (OK):
University of Oklahoma Health Sciences Center; 2016:1-15.
34. Centers for Disease Control and Prevention. Updated guide-
lines for using interferon gamma release assays to detect
Mycobacterium tuberculosis infection d United States, 2010.
MMWR Recomm Rep. 2010;59(RR-5):1-28.35. Canadian tuberculosis standards. 7th ed. Public Health Agency
of Canada. 2014;469:1-468.
36. Tsiouri G, Gaitanis G, Kiorpelidou D, et al. Tuberculin skin test
overestimates tuberculosis hypersensitivity in adult patients
with psoriasis. Dermatology. 2009;219:119-125.
37. Fiorentino D, Langley R, Fakharzadeh S, et al. Malignancy
events in the psoriasis longitudinal assessment and registry
(PSOLAR) study: current status of observations. J Am Acad
Dermatol. 2014:AB175. Abstract P8155.
38. Kimball AB, Schenfeld J, Accortt NA, et al. Incidence rates of
malignancies and hospitalized infectious events in patients
with psoriasis with or without treatment and a general
population in the U.S.A.: 2005-09. Br J Dermatol. 2014;170:
366-373.
39. Margolis D, Bilker W, Hennessy S, et al. The risk of
malignancy associated with psoriasis. Arch Dermatol. 2001;
137:778-783.
40. Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor
alpha inhibitor therapy and cancer risk in chronic
immune-mediated diseases. Arthritis Rheum. 2013;65:48-58.
41. Makredes M, Robinson D Jr, Bala M, Kimball AB. The burden of
autoimmune disease: a comparison of prevalence ratios in
patients with psoriatic arthritis and psoriasis. J Am Acad
Dermatol. 2009;61:405-410.
42. Wu JJ, Nguyen TU, Poon KY, Herrinton LJ. The association of
psoriasis with autoimmune diseases. J Am Acad Dermatol.
2012;67:924-930.
43. Li WQ, Han JL, Chan AT, Qureshi AA. Psoriasis, psoriatic
arthritis and increased risk of incident Crohn’s disease in US
women. Ann Rheum Dis. 2013;72:1200-1205.
44. Egeberg A, Mallbris L, Warren RB, et al. Association between
psoriasis and inflammatory bowel disease - a Danish nation-
wide cohort study. Br J Dermatol. 2016;175:487-492.
45. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human
anti-IL-17A monoclonal antibody, for moderate to severe
Crohn’s disease: unexpected results of a randomized,
double-blind placebo-controlled trial. Gut. 2012;61:1693-1700.
46. Mozaffari S, Nikfar S, Abdollahi M. Inflammatory bowel disease
therapies discontinued between 2009 and 2014. Expert Opin
Investig Drugs. 2015;24:949-956.
47. Kurd SK, Troxel AB, Crits-Christoph P, et al. The risk of
depression, anxiety, and suicidality in patients with psoriasis:
a population-based cohort study. Arch Dermatol. 2010;146:
891-895.
SUPPLEMENTARY APPENDIX
Induction period: ixekizumab versus placebo
(Primary Psoriasis Placebo-Controlled Integrated
Analysis Set; UNCOVER-1,e2, and -3).
During the 12-week induction period, the inci-
dence rates of patients experiencing 1 or more
treatment-emergent adverse event (AE) were higher
in the ixekizumab every 2 week and every 4 week
groups compared with the placebo group.20 Most
treatment-emergent AEs were mild or moderate.
Among individual treatment-emergent AEs occurring
in 1% or more of patients in the total ixekizumab
group, there were higher incidences of injection-site
reactions, nausea, and oropharyngeal pain in the total
ixekizumab group comparedwith the placebo group.
The incidence rates for patients with 1 or more
serious AEs and discontinuations because of AEs did
not significantly differ between the ixekizumab and
placebo groups.20 The most common AE leading to
discontinuation were injection-site reactions in ixe-
kizumab groups and worsening psoriasis in the
placebo group.
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Supplementary Table I. Details of studies comprising integrated data sets
Study type Indication Study identification Design Randomized patients Population Treatment period Treatment(s)
Plaque psoriasisepivotal phase III placebo- and/or active-comparator-controlled clinical studies
Placebo- and
active-controlled
clinical studies
Psoriasis RHAZ NCT01474512 Phase III, multicenter,
randomized,
double-blind,
placebo-controlled,
parallel-group
study
1296 Total patients
(433 ixekizumab
80 mg Q2W; 432
ixekizumab 80 mg
Q4W; 431 placebo)
Patients with
moderate to severe
psoriasis ($10%
BSA involvement,
sPGA score of $3,
PASI score $12 at
baseline) who were
candidates for
systemic therapy
and/or
phototherapy
12-wk Induction
dosing period, 48-
wk maintenance
dosing period (wk
12-60), and 204-wk
LTE period (wk 60-
264)
Induction dosing
period: at wk 0,
ixekizumab 160 mg
or placebo SC
injection;
thereafter,
ixekizumab 80 mg
Q2W or 80 mg Q4W
vs placebo
Maintenance
dosing period:
ixekizumab 80 mg
Q4W or Q12W vs
placebo SC
injection LTE
period: ixekizumab
80 mg Q4W,
ixekizumab 80 mg
Q12W SC injection,
or placebo
Continued
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Supplementary Table I. Cont’d
Study type Indication Study identification Design Randomized patients Population Treatment period Treatment(s)
Placebo- and
active-controlled
clinical studies
Psoriasis RHBA NCT01597245 Phase III, multicenter,
randomized,
double-blind,
placebo-controlled,
active-comparator,
parallel-group
study
1224 Total patients
(351 ixekizumab
80 mg Q2W; 347
ixekizumab 80 mg
Q4W; 358
etanercept; 168
placebo)
Patients with
moderate to severe
psoriasis ($10%
BSA involvement,
sPGA score of $3,
PASI score $12 at
baseline) who were
candidates for
systemic therapy
and/or
phototherapy
12-wk Induction
dosing period, 48-
wk maintenance
dosing period (wk
12-60), and 204-wk
LTE dosing period
(wk 60-264)
Induction dosing
period: at wk 0,
ixekizumab 160 mg
or placebo or
etanercept 50 mg
SC injection;
thereafter,
ixekizumab 80 mg
Q2W or 80 mg Q4W
vs placebo and vs
etanercept 50 mg
(twice weekly) SC
injection
Maintenance dosing
period: ixekizumab
80 mg Q4W or
80 mg Q12W vs
placebo SC
injection
LTE period:
ixekizumab 80 mg
Q4W or 80 mg
Q12W vs placebo
SC injection
RHBC NCT01646177 Phase III, multicenter,
randomized,
double-blind,
placebo-controlled,
active-comparator,
parallel-group
study
1346 Total patients
(193 placebo; 382
etanercept 50 mg
Q2W; 386
ixekizumab 80 mg
Q4W; 385
ixekizumab 80 mg
Q2W)
Patients with
moderate to severe
psoriasis ($10%
BSA involvement,
sPGA score of $3,
PASI score $12 at
baseline) who were
candidates for
systemic therapy
and/or
phototherapy
12-wk Induction
dosing period and
252-wk LTE period
(wk 12-264)
Induction dosing
period: at wk 0,
ixekizumab 160 mg
or placebo or
etanercept 50 mg
SC injection;
thereafter,
ixekizumab 80 mg
Q2W or 80 mg Q4W
vs placebo and vs
etanercept 50 mg
(twice weekly) SC
injection
LTE period:
ixekizumab 80 mg
Q4W SC injection
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Supplementary Table I. Cont’d
Study type Indication Study identification Design Randomized patients Population Treatment period Treatment(s)
Additional clinical studies
Placebo-controlled,
supporting clin-
ical safety studies
Psoriasis RHAJ NCT01107457 Phase II, multicenter,
randomized,
placebo-controlled
study in 2 parts:
part A: 16-wk,
double-blind,
parallel-group,
dose-ranging
design (20 wk;
A/B transition)
and part B: 240-wk,
optional open-label
extension
142 Randomized:
(115 ixekizumab, 27
placebo)
Patients with
moderate to severe
psoriasis ($10%
BSA involvement,
sPGA score of $3,
and PASI total score
$12 at baseline)
who were
candidates for
systemic therapy
Part A: 16-wk, double-
blind, parallel-
group, dose-
ranging design
(20 wk; A/B
transition) and part
B: 240-wk, optional
open-label
extension
Part A: ixekizumab 10,
25, 75, and 150 mg
SC injection at 0, 2,
4, 8, 12, and 16 wk;
placebo SC
injection at 0, 2, 4, 8,
12, and 16 wk
Part B: ixekizumab
120 mg Q4W until
the implementation
of amendment (c),
and thereafter,
ixekizumab 80 mg
Q4W for up to 5 y
(240 wk)
RHAG Phase I, multicenter,
randomized,
double-blind,
placebo-controlled,
dose-escalation,
20-wk study
46 Randomized (37
ixekizumab, 9
placebo)
Patients with severe
psoriasis ($15%
BSA involvement
and PASI total score
$13 at baseline)
who were
candidates for
biological therapy
6 wk Ixekizumab or
placebo Q2W 3 3
doses: 5, 15, 50, and
150 mg SC
injection; 15 mg IV
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Supplementary Table I. Cont’d
Study type Indication Study identification Design Randomized patients Population Treatment period Treatment(s)
Open-label sup-
porting safety
study
Psoriasis RHAT NCT01624233 Phase III, multicenter,
single-arm, open-
label, long-term
study
91 Randomized Japanese patients
with psoriasis
12-wk Induction
dosing period, 40-
wk
Maintenance dosing
period (wk 12-52),
and retreatment
dosing period up to
192 wk after
starting study
retreatment
Induction dosing
period doses: at wk
0, ixekizumab
160 mg SC
injection;
thereafter,
ixekizumab 80 mg
Q2W SC injection
Maintenance and
retreatment
periods dose:
ixekizumab 80 mg
Q4W SC injection
RHBL NCT01777191 Phase III, multicenter,
randomized, open-
label, parallel-
group study
examining the
effect of the drug
delivery device
(prefilled syringe or
autoinjector), the
site of injection
(arm, thigh, or
abdomen), and
body weight on the
pharmacokinetics
after SC
administration of
ixekizumab
204 Randomized Patients with
moderate to severe
plaque psoriasis
12-wk Study, with
optional 40-wk
safety extension:
(wk 12-52)
Randomized study
period: ixekizumab
160 mg loading
dose by SC
injection;
thereafter,
ixekizumab 80 mg
Q2W by prefilled
syringe or
autoinjector
Safety extension
period: ixekizumab
80 mg Q4W by
prefilled syringe
BSA, Body surface area; IV, intravenous; LTE, long-term extension; PASI, Psoriasis Area Severity Index; Q2W, every 2 wk; Q4W, every 4 wk; Q12W, every 12 wk; SC, subcutaneous; sPGA, static Physician
Global Assessment. JA
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Supplementary Table II. Baseline characteristics
Characteristic
PBO- and active-controlled database (UNCOVER-2 and -3)
Maintenance phase (UNCOVER-1 and -2 maintenance dosing
primary population)
All psoriasis IXE
(7 trials)
PBO ETN
IXE 80 mg
Q2W
IXE 80 mg
Q4W IXE total
Withdrawal/
PBO
IXE 80 mg
Q4W
IXE 80 mg
Q12W IXE total All psoriasis IXE
No. of patients 360 739 734 729 1463 402 416 408 824 4209
Age mean, y 45.9 6 12.1 45.5 6 13.3 45.1 6 13.2 45.3 6 13.1 45.2 6 13.2 44.2 6 12.9 43.8 6 13.0 45.4 6 13.0 44.6 6 13.0 45.5 6 13.0
Male, % 71.1 68.2 64.7 68.3 66.5 65.7 69.0 66.2 67.6 67.7
Race, %
Asian 3.6 2.6 3.1 3.0 3.1 4.2 4.1 2.7 3.4 5.5
Black 5.0 3.1 1.4 2.8 2.1 2.5 1.2 2.5 1.8 2.8
White 90.0 92.7 94.1 92.6 93.3 92.3 94.2 93.1 93.7 90.5
Other or multiple 1.4 1.6 1.4 1.7 1.5 1.0 0.5 1.7 1.1 1.2
Geographic region, %
Asia 0 0 0 0 0 1.5 1.2 1.2 1.2 2.9
North America 50.0 51.8 50.4 51.7 51.1 49.5 51.9 50.7 51.3 53.4
Europe 44.2 42.4 43.5 42.2 42.9 44.8 43.8 44.9 44.3 39.2
Central/South
America
3.9 4.1 4.0 4.0 4.0 0 0 0 0 2.4
Australia 1.9 1.8 2.2 2.1 2.1 4.2 3.1 3.2 3.2 2.1
BMI mean, kg/m2 30.5 6 6.7 31.0 6 7.4 30.1 6 7.1 30.6 6 7.0 30.4 6 7.0 30.1 6 6.4 30.1 6 6.7 29.8 6 6.0 30.0 6 6.4 30.6 6 7.2
Prior systemic therapy, %
Never 41.9 39.6 40.1 37.6 38.8 35.6 31.5 25.0 28.3 35.9
Nonbiologic only 36.9 42.1 40.6 42.8 41.7 37.1 35.6 42.6 39.1 36.3
Biologic only 9.7 8.0 7.4 7.0 7.2 9.7 9.9 12.0 10.9 10.6
Biologic and
nonbiologic
11.4 10.3 12.0 12.6 12.3 17.7 23.1 20.3 21.7 17.2
Prior biologic therapy, %
Never 78.9 81.7 80.7 80.4 80.5 72.6 67.1 67.6 67.4 72.2
1 15.6 13.7 12.8 13.6 13.2 18.4 22.6 17.6 20.1 17.3
2 4.4 3.0 4.4 4.0 4.2 5.7 4.3 10.0 7.2 6.0
$3 1.1 1.6 2.2 2.1 2.1 3.2 6.0 4.7 5.3 4.4
Duration of
psoriasis
symptoms mean,
y
18.7 6 12.6 18.5 6 12.1 18.1 6 12.1 18.5 6 12.6 18.3 6 12.4 19.1 6 11.5 19.3 6 12.6 20.1 6 12.6 19.7 6 12.6 18.8 6 12.2
Tobacco use, % 41.6 37.1 38.1 37.6 37.9 39.3 34.9 36.1 35.5 37.5
BMI, Body mass index; ETN, etanercept; IXE, ixekizumab; PBO, placebo; Q2W, every 2 wk; Q4W, every 4 wk; Q12W, every 12 wk.
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Supplementary Table III. Summary of safety in placebo- and active-controlled database (UNCOVER-2 and -3):
weeks 1-12
Summary of TEAE
PBO ETN IXE 80 mg Q2W IXE 80 mg Q4W IXE total
No. of patients 360 739 734 729 1463
Patients with $1 TEAE, n (%) 160 (44.4) 399 (54.0)* 424 (57.8)* 419 (57.5)* 843 (57.6)*
Mild 96 (26.7) 226 (30.6) 225 (30.7) 227 (31.1) 452 (30.9)
Moderate 54 (15.0) 136 (18.4) 177 (24.1) 168 (23.0) 345 (23.6)
Severe 10 (2.8) 36 (4.9) 22 (3.0) 24 (3.3) 46 (3.1)y
Missing 0 1 (0.1) 0 0 0
PY 83.2 169.2 168.9 167.6 336.5
Patients with $1 TEAE, [IR/100 PY] 160 [192.3] 399 [235.8]* 424 [251.1]* 419 [250.0]* 843 [250.5]*
Common TEAEs with incidence $5/100 PY (system organ class and preferred term)z
Infections and infestations 74 [89.0] 159 [93.9] 190 [112.5] 191 [113.9] 381 [113.2]y
Nasopharyngitis 28 [337] 55 [32.5] 61 [36.1] 58 [34.6] 119 [35.4]
Upper respiratory tract infection 12 [14.4] 34 [20.1] 27 [16.0] 24 [14.3] 51 [15.2]
Urinary tract infection 2 [2.4] 5 [3.0] 10 [5.9] 13 [7.8] 23 [6.8]
General disorders and administration site
conditions
30 [36.1] 151 [89.2]* 146 [86.5]* 117 [69.8]*y 263 [78.2]*
Injection-site reaction 4 [4.8] 80 [47.3]* 76 [45.0]* 62 [37.0]* 138 [41.0]*
Injection-site erythema 2 [2.4] 29 [17.1]* 24 [14.2]* 14 [8.4]y 38 [11.3]*
Injection-site pain 5 [6.0] 9 [5.3] 21 [12.4]y 10 [6.0] 31 [9.2]
Fatigue 5 [6.0] 11 [6.5] 13 [7.7] 13 [7.8] 26 [7.7]
Skin and subcutaneous tissue disorders 27 [32.5] 48 [28.4] 72 [42.6]y 71 [41.4]y 143 [42.5]y
Pruritus 5 [6.0] 8 [4.7] 14 [8.3] 16 [9.5] 30 [8.9]
Psoriasis 8 [9.6] 7 [4.1] 9 [5.3] 11 [6.6] 20 [5.9]
Gastrointestinal disorders 17 [20.4] 46 [27.2] 66 [39.1]* 58 [34.6] 124 [36.8]*
Diarrhea 3 [3.6] 8 [4.7] 17 [10.1] 8 [4.8] 25 [7.4]
Nausea 2 [2.4] 3 [1.8] 15 [8.9]y 9 [5.4] 24 [7.1]y
Musculoskeletal and connective tissue disorders 25 [30.1] 44 [26.0] 63 [37.3] 61 [36.4] 124 [36.8]y
Arthralgia 8 [9.6] 17 [10.0] 20 [11.8] 18 [10.7] 38 [11.3]
Back pain 5 [6.0] 7 [4.1] 10 [5.9] 10 [6.0] 20 [5.9]
Nervous system disorders 13 [15.6] 49 [29.0]* 44 [26.1] 53 [31.6]* 97 [28.8]*
Headache 8 [9.6] 31 [18.3] 33 [19.5] 34 [20.3] 67 [19.9]
Injury, poisoning, and procedural complications 21 [25.2] 27 [16.0] 27 [16.0] 42 [25.1] 69 [20.5]
Respiratory, thoracic, and mediastinal disorders 14 [16.8] 29 [17.1] 33 [19.5] 34 [20.3] 67 [19.9]
Oropharyngeal pain 3 [3.6] 7 [4.1] 9 [5.3] 12 [7.2] 21 [6.2]
Cough 1 [1.2] 11 [6.5] 9 [5.3] 10 [6.0] 19 [5.6]
Investigations 12 [14.4] 29 [17.1] 30 [17.8] 22 [13.1] 52 [15.5]
Blood creatine phosphokinase increased 5 [6.0] 7 [4.1] 11 [6.5] 9 [5.4] 20 [5.9]
Metabolism and nutrition disorders 5 [6.0] 23 [13.6] 13 [7.7] 21 [12.5] 34 [10.1]
Vascular disorders 5 [6.0] 20 [11.8] 8 [4.7]y 14 [8.4] 22 [6.5]
Psychiatric disorders 9 [10.8] 11 [6.5] 7 [4.1] 11 [6.6] 18 [5.3]
Blood and lymphatic system disorders 2 [2.4] 11 [6.5] 8 [4.7] 9 [5.4] 17 [5.1]
Patients with $1 SAE, [IR/100 PY] 7 [8.4] 14 [8.3] 14 [8.3] 14 [8.4] 28 [8.3]
SAEs occurring in $2 patients (system organ class and preferred term), n [IR]x
Infections and infestations 2 [2.4] 3 [1.8] 2 [1.2] 5 [3.0] 7 [2.1]
Erysipelas 0 0 0 2 [1.2] 2 [0.6]
Gastrointestinal disorders 1 [1.2] 0 2 [1.2] 2 [1.2] 4 [1.2]
Skin and subcutaneous tissue disorders 2 [2.4] 0 2 [1.2] 1 [0.6] 3 [0.9]
Psychiatric disorders 1 [1.2] 0 2 [1.2] 1 [0.6] 3 [0.9]
Depression 0 0 2 [1.2] 0 2 [0.6]
Suicide attempt 0 0 1 [0.6] 1 [0.6] 2 [0.6]
Metabolism and nutrition disorders 0 0 2 [1.2] 1 [0.6] 3 [0.9]
Hepatobiliary disorders 0 0 2 [1.2] 0 2 [0.6]
Renal and urinary disorders 0 3 [1.8] 1 [0.6] 1 [0.6] 2 [0.6]
Injury, poisoning, and procedural complications 1 [1.2] 1 [0.6] 1 [0.6] 1 [0.6] 2 [0.6]
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Summary of TEAE
PBO ETN IXE 80 mg Q2W IXE 80 mg Q4W IXE total
Nervous system disorders 0 1 [0.6] 0 2 [1.2] 2 [0.6]
Deaths, n [IR] 0 0 0 0 0
Patients with $1 discontinuation because of AEs
(system organ class and preferred term), n [IR]k
3 [3.6] 9 [5.3] 15 [8.9] 14 [8.4] 29 [8.6]
Gastrointestinal disorders 0 0 5 [3.0] 2 [1.2] 7 [2.1]
Diarrhea 0 0 1 [0.6] 1 [0.6] 2 [0.6]
General disorders and administration site
conditions
1 [1.2] 3 [1.8] 3 [1.8] 1 [0.6] 4 [1.2]
Skin and subcutaneous tissue disorders 1 [1.2] 1 [0.6] 2 [1.2] 2 [1.2] 4 [1.2]
Psoriasis 1 [1.2] 0 1 [0.6] 1 [0.6] 2 [0.6]
Infections and infestations 0 0 2 [1.2] 2 [1.2] 4 [1.2]
Injury, poisoning, and procedural complications 0 0 1 [0.6] 1 [0.6] 2 [0.6]
Psychiatric disorders 0 0 1 [0.6] 1 [0.6] 2 [0.6]
Nervous System disorders 0 1 [0.6] 0 2 [1.2] 2 [0.6]
Exposure-adjusted IR for TEAEs represent the number of patients with a particular event/100 PY of exposure. Time during the treatment
period was considered entire exposure time.
Medical Dictionary for Regulatory Activities preferred terms are presented under system organ classification.
AE, Adverse event; ETN, etanercept; IR, incidence rate/100 PY; IXE, ixekizumab; PBO, placebo; PY, patient-years; Q2W, every 2 wk; Q4W, every
4 wk; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
*Statistically significant compared with placebo.
yStatistically significant compared with etanercept.
zTEAEs listed are those that appeared at $5/100 PY in the total IXE treatment group in both studies combined.
xSAEs listed are those that appeared in $2 patients in the total IXE treatment group in both studies combined.
kAEs listed are those that appeared in $2 patients in the total IXE treatment group in both studies combined; includes death.
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Supplementary Table IV. Summary of safety: maintenance phase (UNCOVER-1 and -2 maintenance dosing
period primary population: weeks 12-60)
Withdrawal/
PBO, n [IR]
IXE 80 mg
Q4W, n [IR]
IXE 80 mg
Q12W, n [IR]
IXE total,
n [IR]
No. of patients 402 416 408 824
Total PY 188.2 345.2 282.4 627.6
Patients with $1 TEAE 233 [123.8] 330 [95.6]* 300 [106.2] 630 [100.4]*
Mild 107 [56.8] 138 [40.0] 122 [43.2] 260 [41.4]
Moderate 106 [56.3] 160 [46.4] 152 [53.8] 312 [49.7]
Severe 20 [10.6] 32 [9.3] 26 [9.2] 58 [9.2]
Deaths 0 2 [0.6] 0 2 [0.3]
Common TEAEs with incidence $2/100 PY (system organ class and preferred term)y
Infections and infestations 143 [76.0] 240 [69.5] 206 [72.9] 446 [71.1]
Nasopharyngitis 46 [24.4] 81 [23.5] 65 [23.0] 146 [23.3]
Upper respiratory tract infection 31 [16.5] 43 [12.5] 41 [14.5] 84 [13.4]
Sinusitis 10 [5.3] 18 [5.2] 17 [6.0] 35 [5.6]
Bronchitis 4 [2.1] 13 [3.8] 16 [5.7] 29 [4.6]
Influenza 6 [3.2] 13 [3.8] 14 [5.0] 27 [4.3]
Urinary tract infection 7 [3.7] 15 [4.3] 9 [3.2] 24 [3.8]
Pharyngitis 6 [3.2] 12 [3.5] 11 [3.9] 23 [3.7]
Gastroenteritis 9 [4.8] 8 [2.3] 8 [2.8] 16 [2.5]
Rhinitis 2 [1.1] 5 [1.4] 10 [3.5] 15 [2.4]
Tinea pedis 1 [0.5] 9 [2.6] 5 [1.8] 14 [2.2]
Folliculitis 2 [1.1] 8 [2.3] 5 [1.8] 13 [2.1]
Oral candidiasis 1 [0.5] 7 [2.0] 6 [2.1] 13 [2.1]
Musculoskeletal and connective tissue disorders 41 [21.8] 71 [20.6] 78 [27.6] 149 [23.7]
Arthralgia 13 [6.9] 21 [6.1] 24 [8.5] 45 [7.2]
Back pain 8 [4.2] 15 [4.3] 19 [6.7] 34 [5.4]
Myalgia 1 [0.5] 7 [2.0] 7 [2.5] 14 [2.2]
Skin and subcutaneous tissue disorders 47 [25.0] 71 [20.6] 56 [19.8] 127 [20.2]
Pruritus 3 [1.6] 9 [2.6] 7 [2.5] 16 [2.5]
Psoriasis 9 [4.8] 5 [1.4]* 11 [3.9] 16 [2.5]
Gastrointestinal disorders 35 [18.6] 63 [18.3] 51 [18.1] 114 [18.2]
Diarrhea 12 [6.4] 12 [3.5] 10 [3.5] 22 [3.5]
General disorders and administration site conditions 21 [11.2] 54 [15.6] 46 [16.3] 100 [15.9]
Injection-site reaction 2 [1.1] 27 [7.8]* 11 [3.9] 38 [6.1]*
Injection-site erythema 2 [1.1] 8 [2.3] 7 [2.5] 15 [2.4]
Pyrexia 2 [1.1] 8 [2.3] 5 [1.8] 13 [2.1]
Injury, poisoning, and procedural complications 22 [11.7] 52 [15.1] 32 [11.3] 84 [13.4]
Nervous system disorders 32 [17.0] 35 [10.1]* 45 [15.9] 80 [12.7]
Headache 12 [6.4] 21 [6.1] 25 [8.9] 46 [7.3]
Respiratory, thoracic, and mediastinal disorders 20 [10.6] 40 [11.6] 33 [11.7] 73 [11.6]
Oropharyngeal pain 5 [2.7] 12 [3.5] 9 [3.2] 21 [3.3]
Cough 3 [1.6] 7 [2.0] 7 [2.5] 14 [2.2]
Investigations 15 [8.0] 40 [11.6] 28 [9.9] 68 [10.8]
Blood creatine phosphokinase increased 5 [2.7] 8 [2.3] 8 [2.8] 16 [2.5]
Neoplasms benign, malignant, and unspecified
(including cysts and polyps)
5 [2.7] 14 [4.1] 14 [5.0] 28 [4.5]
Vascular disorders 6 [3.2] 11 [3.2] 12 [4.2] 23 [3.7]
Hypertension 6 [3.2] 8 [2.3] 10 [3.5] 18 [2.9]
Immune system disorders 2 [1.1] 10 [2.9] 10 [3.5] 20 [3.2]
Seasonal allergy 1 [0.5] 8 [2.3] 5 [1.8] 13 [2.1]
Psychiatric disorders 7 [3.7] 8 [2.3] 11 [3.9] 19 [3.0]
Patients with $1 SAE 15 [8.0] 26 [7.5] 23 [8.1] 49 [7.8]
SAEs occurring in $2 patients (system organ class and preferred term)z
Infections and infestations 3 [1.6] 6 [1.7] 3 [1.1] 9 [1.4]
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Withdrawal/
PBO, n [IR]
IXE 80 mg
Q4W, n [IR]
IXE 80 mg
Q12W, n [IR]
IXE total,
n [IR]
Musculoskeletal and connective tissue disorders 1 [0.5] 5 [1.4] 3 [1.1] 8 [1.3]
Osteoarthritis 0 2 [0.6] 1 [0.4] 3 [0.5]
Intervertebral disc protrusion 0 0 2 [0.7] 2 [0.3]
Cardiac disorders 1 [0.5] 3 [0.9] 4 [1.4] 7 [1.1]
Coronary artery disease 0 1 [0.3] 1 [0.4] 2 [0.3]
Gastrointestinal disorders 3 [1.6] 3 [0.9] 2 [0.7] 5 [0.8]
Inguinal hernia 0 1 [0.3] 1 [0.4] 2 [0.3]
Injury, poisoning, and procedural complications 2 [1.1] 4 [1.2] 0 4 [0.6]
Fall 2 [1.1] 2 [0.6] 0 2 [0.3]
Respiratory, thoracic, and mediastinal disorders 2 [1.1] 2 [0.6] 2 [0.7] 4 [0.6]
Hepatobiliary disorders 1 [0.5] 2 [0.6] 1 [0.4] 3 [0.5]
Nervous system disorders 3 [1.6] 1 [0.3] 2 [0.7] 3 [0.5]
Neoplasms benign, malignant, and unspecified 2 [1.1] 1 [0.3] 2 [0.7] 3 [0.5]
General disorders and administration site conditions 0 2 [0.6] 0 2 [0.3]
Vascular disorders 0 0 2 [0.7] 2 [0.3]
Patients with $1 discontinuation from study drug
because of AEs
8 [4.2] 15 [4.3] 9 [3.2] 24 [3.8]
Discontinuations from study drug because of AEs occurring in $2 patients (system organ class and preferred term)x
Investigations 2 [1.1] 5 [1.4] 2 [0.7] 7 [1.1]
Mycobacterium tuberculosis complex test positive 0 3 [0.9] 2 [0.7] 5 [0.8]
Tuberculin test positivek 0 2 [0.6] 0 2 [0.3]
Infections and infestations 1 [0.5] 3 [0.9] 1 [0.4] 4 [0.6]
Latent tuberculosis 0 2 [0.6] 0 2 [0.3]
Cardiac disorders 0 2 [0.6] 0 2 [0.3]
General disorders and administration site conditions 0 2 [0.6] 0 2 [0.3]
Nervous system disorders 0 0 2 [0.7] 2 [0.3]
Exposure-adjusted IR for TEAEs represent the number of patients with a particular event/100 PY of exposure. Time during the treatment
period was considered entire exposure time.
Medical Dictionary for Regulatory Activities preferred terms are presented under system organ classification.
AE, Adverse event; IR, incidence rate/100 PY; IXE, ixekizumab; n, number of patients with at least 1 event in the specified category; PBO,
placebo; PY, patient-years; Q4W, every 4 wk; Q12W, every 12 wk; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
*Statistically significant compared with withdrawal/placebo.
yTEAEs listed are those that appeared at $2/100 PY in the total IXE treatment group.
zSAEs listed are those that occurred in $2 patients in total IXE treatment group.
xAEs listed are those that occurred in $2 patients in the total IXE treatment group; includes death.
kPositive results from tuberculin skin test or interferon gamma release assay in 1 patient each.
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Supplementary Table V. Deaths among patients with psoriasis (all treatment periods)
Patient Age, y Gender
Treatment period at
time of death Study drug dose*
Duration of IXE
exposure Cause of death
Other relevant medical
conditions
1 52 Male Maintenance dosing IXE 80 mg Q4W/IXE 80 mg Q4W 134 Unknown Hypertension; smoking
2 70 Female Maintenance dosing IXE 80 mg Q2W/IXE 80 mg Q4W 246 Myocardial infarction Hypertension; coronary artery
disease; prior myocardial
infarction; type 1 diabetes
mellitus
3 39 Male Long-term extension IXE 80 mg Q4W/IXE 80 mg Q12W 454 Sudden cardiac arrest Dyslipidemia; alcohol abuse
4 66 Female Long-term extension IXE 80 mg Q2W/IXE 80 mg Q4W 219 Hemorrhagic cerebral infarction Prior cerebrovascular accident;
gastric ulcer; gastroesophageal
reflux disease; hypertension;
hyperlipidemia; deep vein
thrombosis; tobacco use
5 55 Male Optional safety extension IXE 80 mg Q2W/IXE 80 mg Q4W 128 Cardiorespiratory arrest Coronary artery disease,
hypertension; type 2 diabetes
mellitus; dyslipidemia; obesity
6 63 Female Long-term extension PBO/IXE 80 mg Q4W 900 Sudden cardiovascular death Obesity; hypertension
7 47 Male Long-term extension IXE 80 mg Q4W/IXE 80 mg Q4W 462 Accidental death Relevant history not available
8 52 Male Long-term extension PBO/IXE 80 mg Q4W 432 Possible myocardial infarction Obesity
9 60 Male Follow-up ETN d Upper gastrointestinal
hemorrhage caused by hepatic
cirrhosis associated with chronic
alcohol misuse
Chronic alcohol misuse; hepatic
enzymes increased
10 60 Male Not randomized Died before randomization d Accidental head trauma d
ETN, Etanercept; IXE, ixekizumab; PBO, placebo; Q2W, every 2 wk; Q4W, every 4 wk; Q12W, every 12 wk.
*Study dose at induction and time of death.
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Supplementary Table VI. Summary of safety in all ixekizumab data set
TEAEs
All psoriasis IXE (7 trials) N = 4209 n [IR]
Total PY 6479.8
Patients with $1 TEAE 3523 [54.4]
TEAEs with adjusted incidence $1.3 in all IXE psoriasis data set (preferred term)
Nasopharyngitis 911 [14.1]
Upper respiratory tract infection 512 [7.9]
Injection-site reaction 441 [6.8]
Headache 313 [4.8]
Arthralgia 270 [4.2]
Sinusitis 225 [3.5]
Back pain 209 [3.2]
Bronchitis 202 [3.1]
Diarrhea 189 [2.9]
Hypertension 172 [2.7]
Urinary tract infection 179 [2.8]
Influenza 161 [2.5]
Pharyngitis 160 [2.5]
Oropharyngeal pain 147 [2.3]
Cough 145 [2.2]
Pruritus 143 [2.2]
Injection-site erythema 139 [2.1]
Psoriasis 135 [2.1]
Blood creatine phosphokinase increased 124 [1.9]
Gastroenteritis 114 [1.8]
Nausea 113 [1.7]
Fatigue 94 [1.5]
Eczema 92 [1.4]
Laceration 91 [1.4]
Vulvovaginal candidiasis* 30 [1.5]
Folliculitis 90 [1.4]
Myalgia 84 [1.3]
Rhinitis 84 [1.3]
Tinea pedis 83 [1.3]
SAE
All psoriasis IXE (7 trials) N = 4209 n [IR]
Total PY 6479.8
Patients with $1 SAE 411 [6.3]
SAEs occurring at a frequency of exposure adjusted rate of $0.1 in all IXE psoriasis data set (preferred term)
Cellulitis 17 [0.3]
Fall 13 [0.2]
Myocardial infarction 11 [0.2]
Osteoarthritis 11 [0.2]
Acute myocardial infarction 9 [0.1]
Chronic obstructive pulmonary disease 8 [0.1]
Nephrolithiasis 8 [0.1]
Suicide attempt 8 [0.1]
Coronary artery disease 7 [0.1]
Depression 6 [0.1]
Inguinal hernia 6 [0.1]
Intervertebral disc protrusion 6 [0.1]
Pneumonia 6 [0.1]
Angina pectoris 5 [0.1]
Angina unstable 5 [0.1]
Appendicitis 5 [0.1]
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Supplementary Table VI. Cont’d
SAE
All psoriasis IXE (7 trials) N = 4209 n [IR]
Cholelithiasis 5 [0.1]
Cholecystitis 5 [0.1]
Diverticulitis 5 [0.1]
Prostate cancery 5 [0.1]
Pulmonary embolism 5 [0.1]
Urinary tract infection 5 [0.1]
Type 2 diabetes mellitus 5 [0.1]
Deep vein thrombosis 4 [0.1]
Dyspnea 4 [0.1]
Hand fracture 4 [0.1]
Road traffic accident 4 [0.1]
Sleep apnea syndrome 4 [0.1]
AEs leading to discontinuation
All psoriasis IXE (7 trials) N = 4209 n [IR]
Total PY 6479.8
Patients with $1 AE leading to discontinuation 252 [3.9]
AEs leading to discontinuation occurring in $2 patients (preferred term)
Mycobacterium tuberculosis complex test positivez 19 [0.3]
Tuberculin test positivex 16 [0.2]
Latent tuberculosis 13 [0.2]
Pregnancy* 4 [0.2]
Maternal exposure during pregnancy* 3 [0.1]
Injection-site reaction 6 [0.1]
Psoriasis 6 [0.1]
Prostate cancery 4 [0.1]
Ulcerative colitis 5 [0.1]
Arthralgia 4 [0.1]
Drug hypersensitivity 4 [0.1]
Pustular psoriasis 4 [0.1]
Suicide attempt 4 [0.1]
Acute myocardial infarction 3 [0.0]
Cellulitis 3 [0.0]
Crohn’s disease 3 [0.0]
Depression 3 [0.0]
Exposure during pregnancy 3 [0.0]
Hepatic enzyme increased 3 [0.0]
Hypersensitivity 3 [0.0]
Myocardial infarction 3 [0.0]
Edema peripheral 3 [0.0]
Psoriatic arthropathy 3 [0.0]
Urticaria 3 [0.0]
Alanine aminotransferase increased 2 [0.0]
Anaphylactic reactionk 2 [0.0]
Appendicitis 2 [0.0]
Aspartate aminotransferase increased 2 [0.0]
Bronchopneumonia 2 [0.0]
Colon cancer 2 [0.0]
Diarrhea 2 [0.0]
Ear infection 2 [0.0]
Headache 2 [0.0]
Hypertension 2 [0.0]
Invasive ductal breast carcinoma 2 [0.0]
Liver function test abnormal 2 [0.0]
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AEs leading to discontinuation
All psoriasis IXE (7 trials) N = 4209 n [IR]
Neutropenia 2 [0.0]
Rash generalized 2 [0.0]
Sciatica 2 [0.0]
Staphylococcal infection 2 [0.0]
Weight decreased 2 [0.0]
Exposure-adjusted IR for TEAEs represent the number of patients with a particular event/100 PY of exposure. Time during the treatment
period was considered entire exposure time.
Medical Dictionary for Regulatory Activities preferred terms are presented.
AE, Adverse event; IR, incidence rate/100 PY; IXE, ixekizumab; N, number of patients in the analysis population; n, number of patients with at
least 1 common AE/TEAE/SAE in the specified category; PY, patient-years; SAE, serious adverse event; TEAE, treatment-emergent adverse
event.
*Denominator adjusted because of gender-specific event for females.
yDenominator adjusted because of gender-specific event for males.
zOne additional patient was discontinued because of investigator decision with a comment ‘‘positive QuantiFERON (Cellestis) tuberculosis.’’
xApproximately 60% of these patients had positive results from interferon gamma release assays.
kThese cases were reported as anaphylaxis, but not confirmed as such after external review. These events occurred approximately
10-14 days after the only IXE dose, which is beyond the expected time frame for anaphylaxis.
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Supplementary Table VII. Summary of selected treatment-emergent adverse events of special interest
PBO- and active-controlled database (UNCOVER-2 and -3)
Maintenance phase (UNCOVER-1 and -2 maintenance
dosing primary population)
All psoriasis
IXE (7 trials)
PBO ETN
IXE 80 mg
Q2W
IXE
80 mg Q4W IXE total
Withdrawal/
PBO n [IR]
IXE 80 mg
Q4W n [IR]
IXE 80 mg
Q12W n [IR]
IXE total
n [IR] All IXE n [IR]
No. of patients 360 739 734 729 1463 402 416 408 824 4209
Total PY 83.2 169.2 168.9 167.6 336.5 188.2 345.2 282.4 627.6 6479.8
Selected adverse events of special interest
Infections and infestations SOC 74 [89.0] 159 [93.9] 190 [112.5] 191 [113.9] 381 [113.2] 143 [76.0] 240 [69.5] 206 [72.9] 446 [71.1] 2537 [39.2]
Candida (HLTs and clinical terms) 2 [2.4] 5 [3.0] 12 [7.1] 4 [2.4] 16 [4.8] 4 [2.1] 16 [4.6] 7 [2.5] 23 [3.7] 165 [2.5]
Oral 0 1 [0.6] 6 [3.6] 1 [0.6] 7 [2.1] 1 [0.5] 9 [2.6] 6 [2.1] 15 [2.4] 78 [1.2]
Vulvovaginal* 1 [4.2] 2 [3.7] 2 [3.3] 3 [5.6] 5 [4.4] 1 [1.6] 3 [2.8] 1 [1.1] 4 [2.0] 50 [2.4]
Skin 1 [1.2] 0 3 [1.8] 0 3 [0.9] 1 [0.5] 4 [1.2] 1 [0.4] 5 [0.8] 25 [0.4]
Esophageal 0 0 1 [0.6] 0 1 [0.3] 1 [0.5] 1 [0.3] 0 1 [0.2] 7y [0.1]
Nail 0 0 0 0 0 0 0 0 0 1 [0]
Unspecified 0 0 0 0 0 0 0 0 0 18 [0.3]
MACEz 1 [1.2] 1 [0.6] 0 1 [0.6] 1 [0.3] 1 [0.5] 3 [0.9] 0 3 [0.5] 38 [0.6]x
Crohn’s disease 0 0 1 [0.6] 0 1 [0.3] 3 [1.6] 0 0 0 5 [0.1]
Ulcerative colitis 0 0 1 [0.6] 0 1 [0.3] 0 1 [0.3] 2 [0.7] 3 [0.5] 10 [0.2]
Malignancy, excluding NMSC 0 1 [0.6] 1 [0.6] 0 1 [0.3] 1 [0.5] 0 2 [0.7] 2 [0.3] 33 [0.5]
Malignancy, NMSC 0 0 2 [1.2] 0 2 [0.6] 0 1 [0.3] 3 [1.1] 4 [0.6] 27 [0.4]
Selected serious adverse events of special interest
Infections and infestations SOC 2 [2.4] 3 [1.8] 2 [1.2] 5 [3.0] 7 [2.1] 3 [1.6] 6 [1.7] 3 [1.1] 9 [1.4] 87 [1.3]
Candida (HLTs and clinical terms) 0 0 0 0 0 0 0 0 0 2 [0]
MACEz 1 [1.2] 1 [0.6] 0 1 [0.6] 1 [0.3] 1 [0.5] 3 [0.9] 0 3 [0.5] 37 [0.6]x
Crohn’s disease 0 0 1 [0.6] 0 1 [0.3] 2 [1.1] 0 0 0 3 [0]
Ulcerative colitis 0 0 0 0 0 0 0 1 [0.4] 1 [0.2] 3 [0]
Malignancy, excluding NMSC 0 1 [0.6] 0 0 0 1 [0.5] 0 2 [0.7] 2 [0.3] 24 [0.3]
Malignancy, NMSC 0 0 0 0 0 0 0 0 0 4 [0.1]
Exposure-adjusted IR for treatment-emergent adverse events represent the number of patients with a particular event/100 PY of exposure. Time during the treatment period was considered entire
exposure time.
Preferred terms and groupings are presented.
ETN, Etanercept; HLT, high-level term; IR, incidence rate/100 PY; IXE, ixekizumab; MACE, major adverse cardiovascular events; NMSC, nonmelanoma skin cancer; PBO, placebo; PY, patient-years; Q2W,
every 2 wk; Q4W, every 4 wk; Q12W, every 12 wk; SOC, system organ class.
*Denominator adjusted because of gender-specific event for females.
yThere was an additional patient with esophageal candidiasis who had been recently re-randomized from IXE to placebo.
zOnly events confirmed after adjudication; only phase III studies were adjudicated.
xTotal PY for adjudicated trials = 6026.4.
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Supplementary Table VIII. Additional adverse events of special interest
PBO- and active-controlled database (UNCOVER-2 and -3)
Maintenance phase (UNCOVER-1 and -2
maintenance dosing primary population)
All Psoriasis
IXE (7 trials)
PBO
n [IR]
ETN
n [IR]
IXE 80 mg
Q2W n [IR]
IXE 80 mg
Q4W n [IR]
IXE total
n [IR]
Withdrawal/
PBO n [IR]
IXE 80 mg
Q4W n [IR]
IXE 80 mg
Q12W n [IR]
IXE total
n [IR]
All psoriasis
IXE n [IR]
No. of patients 360 739 734 729 1463 402 416 408 824 4209
Total PY 83.2 169.2 168.9 167.6 336.5 188.2 345.2 282.4 627.6 6479.8
Depression and suicide/self-injury occurring
in $1 patient, n [IR]
2 [2.4] 6 [3.5] 3 [1.8] 3 [1.8] 6 [1.8] 2 [1.1] 5 [1.4] 5 [1.8] 10 [1.6] 86 [1.3]*
Depression 1 [1.2] 3 [1.8] 3 [1.8] 2 [1.2] 5 [1.5] 2 [1.1] 3 [0.9] 4 [1.4] 7 [1.1] 62 [1.0]
Suicide attempt 0y 0 1 [0.6] 1 [0.6] 2 [0.6] 0 0 1 [0.4] 1 [0.2] 8 [0.1]
Mood swings 0 0 0 1 [0.6] 1 [0.3] 0 0 0 0 3 [0.0]
Depressed mood 1 [1.2] 1 [0.6] 0 0 0 0 0 0 0 3 [0.0]
Apathy 0 1 [0.6] 0 0 0 0 0 0 0 0
Hypersomnia 0 1 [0.6] 0 0 0 0 0 0 0 0
Suicidal ideation 0 1 [0.6] 0 0 0 0 0 0 0 1 [0.0]
Alcohol abuse 0 0 0 0 0 0 1 [0.3] 0 1 [0.2] 2 [0.0]
Alcohol poisoning 0 0 0 0 0 0 1 [0.3] 0 1 [0.2] 4 [0.1]
Initial insomnia 0 0 0 0 0 0 0 0 0 2 [0.0]
Completed suicide 0 0 0 0 0 0 0 0 0 0
Malignancy occurring in $1 patient, n [IR] 0 1 [0.6] 3 [1.8] 0 3 [0.9] 1 [0.5] 1 [0.3] 5 [1.8] 6 [1.0] 60 [0.9]z
NMSC 0 0 2 [1.2] 0 2 [0.6] 0 1 [0.3] 3 [1.1] 4 [0.6] 27 [0.4]
Basal cell carcinoma 0 0 2 [1.2] 0 2 [0.6] 0 0 2 [0.7] 2 [0.3] 20 [0.3]
Squamous cell carcinoma 0 0 0 0 0 0 1 [0.3] 1 [0.4] 2 [0.3] 8 [0.1]x
Malignancies excluding NMSC 0 1 [0.6] 1 [0.6] 0 1 [0.3] 1 [0.5] 0 2 [0.7] 2 [0.3] 33 [0.5]
Thyroid neoplasm 0 0 1 [0.6] 0 1 [0.3] 0 0 0 0 5 [0.1]
Malignant melanoma 0 1 [0.6] 0 0 0 0 0 0 0 0
Invasive ductal breast carcinoma 0 0 0 0 0 0 0 0 0 2 [0.0]
Thyroid cancer 0 0 0 0 0 0 0 0 0 1 [0.0]
Prostate cancerk 0 0 0 0 0 0 0 1 [0.5] 1 [0.2] 5 [0.1]
Small intestine adenocarcinoma 0 0 0 0 0 0 0 1 [0.4] 1 [0.2] 1 [0.0]
Papillary thyroid cancer 0 0 0 0 0 1 [0.5] 0 0 0 0
B-cell lymphoma 0 0 0 0 0 0 0 0 0 2 [0.0]
Colon cancer 0 0 0 0 0 0 0 0 0 2 [0.0]
MACE occurring in $1 patient,{ n [IR] 1 [1.2] 1 [0.6] 0 1 [0.6] 1 [0.3] 1 [0.5] 3 [0.9] 0 3 [0.5] 38 [0.6]
No. of patients 360 739 734 729 1463 402 416 408 824 4035#
Total PY 83.2 169.2 168.9 167.6 336.5 188.2 345.2 282.4 627.6 6026.4#
Vascular death** 0 0 0 0 0 0 2 [0.6] 0 2 [0.3] 7 [0.1]
Death 0 0 0 0 0 0 1 [0.3] 0 1 [0.2] 1 [0.0]
MI 0 0 0 0 0 0 1 [0.3] 0 1 [0.2] 2 [0.0]
Cardiac arrest 0 0 0 0 0 0 0 0 0 1 [0.0]
Continued
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Supplementary Table VIII. Cont’d
PBO- and active-controlled database (UNCOVER-2 and -3)
Maintenance phase (UNCOVER-1 and -2
maintenance dosing primary population)
All Psoriasis
IXE (7 trials)
PBO
n [IR]
ETN
n [IR]
IXE 80 mg
Q2W n [IR]
IXE 80 mg
Q4W n [IR]
IXE total
n [IR]
Withdrawal/
PBO n [IR]
IXE 80 mg
Q4W n [IR]
IXE 80 mg
Q12W n [IR]
IXE total
n [IR]
All psoriasis
IXE n [IR]
Cardiorespiratory arrest 0 0 0 0 0 0 0 0 0 1 [0.0]
Coronary artery disease 0 0 0 0 0 0 0 0 0 1 [0.0]
Hemorrhagic cerebral infarction 0 0 0 0 0 0 0 0 0 1 [0.0]
Nonfatal MIyy 1 [1.2] 1 [0.6] 0 0 0 0 1 [0.3] 0 1 [0.2] 25 [0.4]
Acute MI 1 [1.2] 0 0 0 0 0 1 [0.3] 0 1 [0.2] 9 [0.1]
MI 0 1 [0.6] 0 0 0 0 0 0 0 9 [0.1]
Angina pectoris 0 0 0 0 0 0 0 0 0 2 [0.0]
Angina unstable 0 0 0 0 0 0 0 0 0 2 [0.0]
Acute coronary syndrome 0 0 0 0 0 0 0 0 0 1 [0.0]
Arteriospasm coronary 0 0 0 0 0 0 0 0 0 1 [0.0]
Stress cardiomyopathy 0 0 0 0 0 0 0 0 0 1 [0.0]
Nonfatal strokezz 0 0 0 1 [0.6] 1 [0.3] 1 [0.5] 0 0 0 6 [0.1]
Ischemic stroke 0 0 0 1 [0.6] 1 [0.3] 1 [0.5] 0 0 0 6 [0.1]
Ischemic stroke 0 0 0 0 0 1 [0.5] 0 0 0 1 [0.0]
Cerebral artery embolism 0 0 0 1 [0.6] 1 [0.3] 0 0 0 0 1 [0.0]
Cerebrovascular accident 0 0 0 0 0 0 0 0 0 1 [0.0]
Hemiparesis 0 0 0 0 0 0 0 0 0 1 [0.0]
Lacunar infarction 0 0 0 0 0 0 0 0 0 1 [0.0]
Optic ischemic neuropathy 0 0 0 0 0 0 0 0 0 1 [0.0]
Exposure-adjusted IR for treatment-emergent adverse events represent the number of patients with a particular event/100 PY of exposure. Time during the treatment period was considered entire
exposure time.
Medical Dictionary for Regulatory Activities preferred terms under groupings are presented.
ETN, Etanercept; IR, incidence rate; IXE, ixekizumab;MACE, major adverse cardiovascular events; MI, myocardial infarction; N, number of patients in the analysis population; n, number of patients with
at least 1 event in the specified category; NMSC, nonmelanoma skin cancer; PBO, placebo; PY, patient-years; Q2W, every 2 wk; Q4W, every 4 wk; Q12W, every 12 wk.
*In addition to the listed treatment-emergent adverse events, the following additional treatment-emergent adverse events occurred in 1 patient each in the all psoriasis data set: alcoholism, drug
dependence, dysphoria, dyssomnia, emotional distress, intentional overdose, major depression, memory impairment, poor quality sleep, and substance abuse.
yThere was 1 suicide attempt in the phase I study, which was not counted in the Psoriasis Placebo- and Active-Controlled Integrated Analysis Set database.
zIn addition to the listed treatment-emergent adverse events, the following additional treatment-emergent adverse events occurred in 1 patient each in the all psoriasis data set: vulval cancer,
metastatic prostate cancer, breast cancer, lip squamous cell carcinoma, malignant lung neoplasm, metastases to liver, metastases to lung, malignant neoplasm, metastatic nonsmall cell lung cancer,
rectal adenocarcinoma, rectal cancer, renal cancer stage II, renal cell carcinoma, renal neoplasm, squamous cell carcinoma, squamous cell carcinoma of lung, synovial sarcoma, tonsillar neoplasm,
and transitional cell carcinoma.
xIncludes 1 case of Bowen disease.
kDenominator adjusted because of gender-specific event for males.
{Adjudicated Antithrombotic Trialists’ Collaboration Events.
#Adjudication was performed only for the following studies: RHAT, UNCOVER-1, UNCOVER-2, UNCOVER-3, and RHBL.
**Includes cardiovascular and cerebrovascular causes excluding hemorrhagic deaths outside of the central nervous system.
yyThese reported events were adjudicated as nonfatal MIs.
zzNonfatal stroke includes ischemic, hemorrhagic, and unknown stroke type.
J
A
M
A
C
A
D
D
E
R
M
A
T
O
L
n
20
16
9
.e
1
7
Stro
b
er
et
a
l
